GLYC Crescent Biopharma Inc.


$ 13.07 $ -0.02 (-0.15 %)    

Friday, 21-Nov-2025 15:56:30 EST
QQQ $ 589.60 $ 4.40 (0.75 %)
DIA $ 462.45 $ 5.05 (1.1 %)
SPY $ 658.47 $ 6.50 (1 %)
TLT $ 89.50 $ 0.27 (0.3 %)
GLD $ 373.70 $ -0.58 (-0.15 %)
$ 13.06
$ 13.25
$ 13.06 x 10
$ 13.10 x 103
$ 12.84 - $ 13.09
$ 9.81 - $ 37.00
24,801
na
na
$ 1.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 glycomimetics-merger-bound-crescent-appoints-joshua-brumm-as-ceo

Crescent also appointed Jonathan McNeill, president and chief operating officer; Ellie Im, M.D., chief medical officer; Rick Sc...

 cantor-fitzgerald-initiates-coverage-on-glycomimetics-with-overweight-rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on GlycoMimetics (NASDAQ:GLYC) with a Overweight rating.

 glycomimetics-and-crescent-amend-merger-agreement-crescent-to-own-9690-post-merger-200m-securities-purchase-reallocated-ownership-and-exchange-ratio-unchanged-18m-net-cash-at-closing

- SEC Filing

 glycomimetics-shares-are-soaring-tuesday-heres-why

GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent B...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION